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Background/Aims: Many studies have compared patients with systemic lupus erythematosus (SLE) on renal
replacement therapy (RRT) with non-lupus patients. However, few data are available on the long-term outcome of
patients with end-stage renal disease (ESRD) secondary to SLE who are managed by different types of RRTs.
Methods: We conducted a retrospective multicenter study on 59 patients with ESRD who underwent mainte-
nance RRT between 1990 and 2007 for SLE. Of these patients, 28 underwent hemodialysis (HD), 14 underwent
peritoneal dialysis (PD), and 17 patients received kidney transplantation (KT). We analyzed the clinical outcomes
in these patients to determine the best treatment modality.
Results: The mean follow-up period was 5 ± 3 years in the HD group, 5 ± 3 years in the PD group, and 10 ± 5
years in the KT group (p = 0.005). Disease flare-up was more common in the HD group than in the KT group (p =
0.012). Infection was more common in the PD and HD groups than in the KT group (HD vs. KT, p = 0.027; PD
vs. KT, p = 0.033). Cardiovascular complications were more common in the HD group than in the other groups (p
= 0.049). Orthopedic complications were more common in the PD group than in the other groups (p = 0.028).
Bleeding was more common in the HD group than in the other groups (p = 0.026). Patient survival was greater in
the KT group than in the HD group (p = 0.029). Technique survival was lower in the PD group than in the HD
group (p = 0.019).
Conclusions: Among patients with ESRD secondary to SLE, KT had better patient survival and lower complica-
tion rates than HD and lower complication rates than PD. The prognosis between the HD and PD groups was
similar. We conclude that if KT is not a viable treatment option, any alternative treatment should take into
account the patient’s general condition and preference. (Korean J Intern Med 2011;26:60-67)
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INTRODUCTION
Lupus nephritis develops in 60% of patients with sys-
temic lupus erythematosus (SLE), and 20% of patients
with lupus nephritis develop end-stage renal disease
(ESRD) within 10 years of disease onset [1]. Although
renal involvement in SLE is frequent and important,
patients with ESRD secondary to SLE are relatively
uncommon. As such, few studies have focused on patients
having SLE treated with renal replacement therapy
(RRT), and choosing the appropriate RRT is an important
consideration to maximize survival and quality of life inKang SH, et al. Outcomes by RRT in patients with lupus nephritis    61
these patients.
Previous studies have reported similar cumulative sur-
vival rates between patients with SLE and non-SLE
patients who received renal RRT [2-4]. These studies pro-
vide a limited comparison across a small number of RRT
modalities and focus on changes in disease activity.
Limited evidence exists on the long-term clinical course of
these patients treated with different RRT modalities,
including kidney transplantation (KT). Additionally, since
most reviews on patients with SLE treated using RRT rely
on meta-analysis outcomes, controversies exist regarding
the clinical courses and survival rates in patients treated
with different RRT modalities [1].
To address this controversy, we conducted a retrospec-
tive multicenter study evaluating the clinical courses and
survival of patients with SLE managed by three different
RRT modalities. Results based on these data were used to
determine the best treatment modality among three RRTs
in patients with ESRD secondary to SLE.
METHODS
Patient enrollment and characteristics
We examined the medical records of patients diagnosed
with SLE, according to criteria established by the
American College of Rheumatology [5], who underwent
RRT in Korea from 1990 to 2007 at four tertiary medical
centers: Seoul St. Mary’s Hospital, St. Mary’s Hospital,
Uijeongbu St. Mary’s Hospital, and St. Vincent’s Hospital.
Patients who received RRT for less than 3 months were
excluded from this study. Of the 59 patients enrolled in
the study, 28 received hemodialysis (HD), 14 had peri-
toneal dialysis (PD), and 17 underwent KT. The following
data were documented from patient records: gender, age,
onset of disease, duration of RRT, predominant RRT prior
to KT (defined as the one used for > 50% of the total dura-
tion of ESRD prior to KT [6]), disease flare-up (defined as
an increase of ≥ 1.0 on a physician’s global assessment as
compared to the previous visit [7]), infection, malignancy,
cardiovascular accident, orthopedic disease, bleeding,
newly developed and/or aggravated diabetes mellitus
(DM) or hypertension (HTN), and survival. Except DM
and HTN, only hospital admission records were included
in this study. In case of aggravated DM and HTN, the
doses and number of medications before RRT were com-
pared with that prescribed at their last visit after RRT.
Statistical analysis
Data were analyzed using SPSS version 15.0 (SPSS Inc.,
Chicago, IL, USA). Comparisons of events among the HD,
PD, and KT groups were performed using one-way analy-
sis of variance (ANOVA) and an independent t test. In the
present study, we introduced episode/patient-year to
adjust for different follow-up periods and compared this
ratio using a t test. Patient, technique, and graft survival
estimates were calculated using the Kaplan-Meier analy-
sis. Survival estimates between groups were compared
with the log-rank test; p < 0.05 was considered to be sta-
tistically significant.
RESULTS
Baseline characteristics
Demographic characteristics of patients following ESRD
onset are shown in Table 1. The population studied was
predominantly female (83%). Age at SLE diagnosis was
30 ± 13 years in the HD group, 33 ± 11 years in the PD
group, and 27 ± 8 years in the KT group. Age at ESRD
onset in the HD, PD, and KT groups were 35 ± 12, 41 ± 10,
and 33 ± 8 years, respectively. The intervals from SLE
diagnosis to ESRD were 6.6 ± 4.6 years in the HD group,
8.2 ± 6.9 years in the PD group, and 7.4 ± 5.5 years in the
Table 1. Demographic characteristics of the patients
HD (n = 28) PD (n = 14) KT (n = 17) p value
Gender (male:female)  5:23 1:13 4:13 0.543
Age of diagnosis of lupus nephritis, yr  30 ± 13 33 ± 11 27 ± 8 0.294
Age at ESRD, yr 35 ± 12 41 ± 10 33 ± 8 0.157
Follow-up since ESRD, yr 5 ± 3 5 ± 3 10 ± 5 .4 0.005
Interval from SLE to ESRD, yr 6.6 ± 4.6 8.2 ± 6.9 7.4 ± 5.5 0.649
Values are presented as number or mean ± SD.
HD, hemodialysis; PD, peritoneal dialysis; KT, kidney transplantation; ESRD, end-stage renal disease; SLE, systemic lupus erythematosus.62 The Korean Journal of Internal Medicine Vol. 26, No. 1, March 2011
KT group. The mean follow-up periods of the HD, PD, and
KT groups were 5 ± 3, 5 ± 3, and 10 ± 5 years, respectively.
The HD, PD, and KT groups all showed similar mean age
of SLE onset and interval from SLE diagnosis to ESRD.
The mean follow-up period of the KT group was longer
than that of the HD and PD groups (p = 0.005). Prior to
undergoing KT, 10 patients predominantly underwent HD
and 6 patients predominantly received PD. One patient
did not have dialysis prior to KT. The durations of dialysis
prior to KT were 30 ± 32 months for HD and 36 ± 39
months for PD. No significant difference was observed in
the duration of RRT prior to KT.
Clinical outcomes analyses
Table 2 summarizes the patterns of disease flare-up in
the study patients. SLE flare-up occurred in 9 patients
who underwent HD (29%, 0.52 episode/patient-year), 4
patients who received PD (32%, 0.22 episode/patient-
year), and 1 patient who had a KT (6%, 0.01 episode/patient-
year). Disease flare-up was more common in the HD
group than in the KT group (p = 0.012) and the
episode/patient-year remained the same. No significant
difference in disease flare-up was observed among the
other groups. Patients on HD and PD developed compli-
cations including fever, central nervous system (CNS)
manifestation of SLE, pulmonary hemorrhage, hemato-
logic manifestation, vasculitis, and pancreatitis. Only 1
patient who had a KT developed hematologic manifesta-
tions of SLE. 
Table 3 summarizes the infection episodes in the study
patients. Infection occurred in 13 patients in the HD group
(46%, 0.64 episode/patient-year), 11 patients in the PD
group (79%, 0.36 episode/patient-year), and 10 patients
in the KT group (59%, 0.15 episode/patient-year). When
comparing the three groups, infection by episode/patient-
year was more common in the HD and PD groups than in
the KT group (HD vs. KT, p = 0.027; PD vs. KT, p =
0.033). These events included pneumonia, tuberculosis,
viral infection, sepsis, skin and soft tissue infection, and
fungal infection. Pneumonia was the most common infec-
tion in the HD and PD groups (14% and 14%, respective-
ly), and viral infection was the most common infection in
the KT group (35%). Severe infection such as tuberculosis
or sepsis was more common in the HD group. Cardiovascular
complications occurred in 8 patients in the HD group
(29%, 0.18 episode/patient-year), 2 in the PD group (14%,
0.09 episode/patient-year), and none in the KT group.
Comparing the three groups, cardiovascular complica-
Table 2. Patterns of SLE flare-up during renal replacement therapy
HD PD KT p value
Fever 2  (7.1) 0 0 0.354
CNS manifestation  5 (17.8) 1 (7.1) 0 0.146
Pulmonary hemorrhage  1 (3.6) 1 (7.1) 0 0.722
Pancreatitis 0 1  (7.1) 0 0.237
Vasculitis 0 1  (7.1) 0 0.237
Hematologic manifestation  5 (17.8) 1 (7.1) 1 (5.9) 0.459
Values are presented as number (%).
SLE, systemic lupus erythematosus; HD, hemodialysis; PD, peritoneal dialysis; KT, kidney transplantation; CNS, central nervous system.
Table 3. Types of infection during renal replacement therapy
HD PD KT p value
Pneumonia  4 (14) 2 (14) 4 (24) 0.180
Tuberculosis 3  (11) 1  (7.1) 0 0.043
Viral infection  3 (11) 2 (14) 6 (35) 0.057
Sepsis 1  (3.6) 0 0 0.237
Skin and soft tissue  2 (7.1) 1 (7.1) 1 (5.9) 0.572
Fungal infection  2 (7.1) 0 1 (5.9) 0.080
Others 1  (3.6)a 0 1 (5.9)a 0.493
Values are presented as the number (%).
HD, hemodialysis; PD, peritoneal dialysis; KT, kidney transplantation.
aIntra-abdominal abscess in the HD group; urinary tract infection in the KT group.Kang SH, et al. Outcomes by RRT in patients with lupus nephritis    63
tions were more common in the HD group than in the PD
and KT groups (p = 0.049), although no significant differ-
ence was observed by episode/patient-year. When com-
paring the HD and KT groups, cardiovascular complica-
tions were more common in the HD group (p = 0.004),
although no difference was observed by episode/patient-
year. Five patients in the HD group developed an arteri-
ovenous fistula problem. Dilated cardiomyopathy, uncon-
trolled hypertension, and heart failure developed in one
patient in the HD group. Orthostatic hypotension and
heart failure developed in one patient who received PD.
Additional complications were noted in the study popu-
lation, including malignancies, orthopedic disease, bleed-
ing, aggravated DM, and HT. Malignancy occurred in 3
patients in the HD group (11%, 0.03 episode/patient-year)
who were diagnosed with breast, stomach, or cervical can-
cer. None of the patients in the PD group developed a
malignancy and 2 in the KT group (12%, 0.01 episode
/patient-year) developed stomach cancer or thymoma.
Orthopedic complications occurred in 1 patient in the HD
group (4%, 0.002 episode/patient-year), 3 in the PD
group (21%, 0.07 episode/patient-year), and 2 patients in
the KT group (12%, 0.01 episode/patient-year).
Orthopedic complications by episode/patient-year were
more common in the PD group than in other groups (p =
0.028). One patient in the HD group developed rhab-
domyolysis of unknown cause, 2 patients in the PD group
developed avascular necrosis of the femur head (AVN), 1
patient in the PD group developed compression fracture
of the spine, and 2 patients in the KT group developed
AVN.  
Bleeding occurred in 8 patients in the HD group (29%,
0.22 episode/patient-year), none in the PD group, and 1
patient in the KT group (6%, 0.004 episode/patient-year).
Bleeding was more common in the HD group than in
other groups (p = 0.026), although the difference was not
significant (p = 0.053) by episode/patient-year. When
comparing bleeding between the HD group and the KT
and PD groups, it was more common in the HD group
than in the others (HD vs. KT, p = 0.033; HD vs. PD, p =
0.004). Similar results were obtained by episode/patient-
year. In the HD group, 7 patients developed gastrointesti-
nal bleeding, 2 developed bleeding of the vascular access,
and 1 patient developed vaginal bleeding. One patient in
the KT group developed postoperative hematoma in the
perinephric space. 
Aggravated DM occurred in 2 patients (7%, 0.04
episode/patient-year) in the HD group, no patients in the
PD group, and 2 patients in the KT group (18%, 0.02
episode/patient-year). Aggravated HTN occurred in 9
patients on HD (32%, 0.25 episode/patient-year), 6 PD
patients on PD (43%, 0.18 episode/patient-year), and 8
patients who received a KT (47%, 0.44 episode/patient-
year). No significant difference was observed in aggravat-
ed HTN and/or DM.
Survival analysis
Cumulative survival rates at 5 and 10 years were 100%
and 90% in the KT group, 93% and 81% in the PD group,
and 79% and 55% in the HD group, respectively (Fig. 1).
When comparing two groups separately, survival was
higher in the KT group than in the HD group (p = 0.029),
but no significant difference was observed between the
HD and PD groups (p= 0.334) in survival rates.  
Twelve deaths were recorded and Table 4 shows the
causes of death by RRT modality. Disease flare-up, infec-
tion, cardiovascular disease, malignancy, and bleeding
were the causes of death in patients with SLE on RRT.
Regarding the PD group, 2 patients died of disease flare-
up (CNS lupus, infection following pancytopenia), 1 died
due to infection, and another succumbed to cardiovascu-
lar disease. In the HD group, 2 patients died of cardiovas-
Table 4. Type of cause of death according to the treatment modality
HD PD KT
Disease flare-upa 1 (14) 2 (50) 0
Infection  1 (14) 1 (25) 0
Cardiovascular disease  2 (29) 1 (25) 0
Malignancy 2  (29) 0 1  (100)
Bleeding 1  (14) 0 0
Values are presented as the number (%).
HD, hemodialysis; PD, peritoneal dialysis; KT, kidney transplantation.
aOne patient on HD died from pulmonary hemorrhage, 2 patients on PD died from infection following pancytopenia and central nervous system
lupus.64 The Korean Journal of Internal Medicine Vol. 26, No. 1, March 2011
cular disease, 2 died due to malignancy, 1 died of disease
flare-up (pulmonary hemorrhage), 1 died due to infection,
and 1 patient died due to bleeding. Except for 1 patient
who succumbed to recurrent thymoma, no other patient
died in the KT group. 
Technique or graft survival rates at 5 and 10 years were
89% and 89% in the KT group, 70% and 23% in the PD
group, and 86% and 86% in the HD group, respectively
(Fig. 2). Technique survival rate was lower in the PD
group than in the HD group (p = 0.019). The causes of
technique failure in the PD group were peritonitis in 5
patients, perihepatic abscess in 1 patient, and recurrent
pancreatitis in 1 patient. The causes of technique failure in
the HD group were vascular access infection in 1 patient
and bleeding of vascular access in another patient.
Rejection occurred in 1 patient who underwent KT.
DISCUSSION
The age at ESRD onset is much younger in patients with
SLE than in the general RRT population [8,9]. Thus,
choosing the appropriate RRT modality is important to
maximize survival and the quality of life in patients with
ESRD secondary to SLE. We conducted a retrospective
multicenter study evaluating the clinical courses and sur-
vival of patients with SLE managed by three different RRT
modalities to determine the best treatment option among
three RRTs in patients with SLE and ESRD. The results
showed that KT had a higher survival and lower complica-
tion rates than HD and lower complication rates than PD.
We found that, in most complications such as disease
flare-up, infection, orthopedic complication, bleeding, and
survival rate, KT is superior to HD and PD. Note, howev-
er, that the mean follow-up period of the KT group was
longer than that of the other groups. When comparing HD
with PD, PD was better than HD across most study out-
comes except in orthopedic complications. However, the
technique survival rate of PD was lower than that of HD
and we believe that patients undergoing PD received an
early modality change following failure of the procedure.
Disease activity in patients with SLE that progressed to
ESRD has been studied extensively, and SLE disease
activity was found to decline following RRT commence-
ment, except in PD in most studies [1-3,10,11]. This study
showed that SLE flare-up in patients on RRT was less
common in the KT group. Although issues regarding
immunosuppressant use are not mentioned in the current
study, most patients in the KT group had been using cal-
cineurin inhibitors and steroids, whereas most patients in
the other groups only received steroids. Thus, we think
that disease flare-up control was associated with proper
immunosuppressant use, such as calcineurin inhibitors
[12,13], and bioincompatibility by the dialysate or dialyzer.
Our data also determined that KT was superior to HD and
PD in infection control and severity. Because of the
immunosuppressive regimens administered to prevent
allograft rejection after KT, and the immunosuppressive
actions of ESRD prior to transplantation, several investi-
gators mistakenly assumed that infections were more
Figure 1. Patient survival according to the treatment modality.
Survival was higher in the KT group than in the HD group (p =
0.029, tested by log rank test), but no significant difference was
observed between the HD group and the PD group (p = 0.334).
KT, kidney transplantation; PD, peritoneal dialysis; HD,
hemodialysis.
Figure 2. Technique survival according to the treatment
modality. Technique survival rate was lower in the PD group
than in the HD group (p=0.019, tested by log rank test). PD,
peritoneal dialysis; HD, hemodialysis.Kang SH, et al. Outcomes by RRT in patients with lupus nephritis    65
common in patients who underwent KT [14]. The infec-
tion risk of patients in the KT group was actually the
smallest among RRTs, especially severe infections includ-
ing tuberculosis and sepsis, although less severe infections
including viral infections were more common. The reason
for this low infection risk after KT remains unclear.
Contrary to KT, patients with SLE on dialysis are known
to be at an increased risk of infection compared to non-
lupus patients on dialysis [15].
No significant differences were observed in cardiovascu-
lar complications or malignancies between RRT modali-
ties. Hemodynamic instability, aneurysm of vascular
access, and thrombosis in the HD group may have been
related to frequent cardiovascular complications, consis-
tent with previous studies [3]. Patients with ESRD sec-
ondary to SLE have little comorbidity due to short disease
duration, rapid disease progression, and relatively young
age. Therefore, the pattern of cardiovascular disease is dif-
ferent from that in non-lupus patients. Critical cardiovas-
cular diseases such as coronary heart disease are more
common in non-lupus patients than in patients with SLE.
As survival improves, the pattern of cardiovascular disease
will be more critical in patients with SLE. We hypothesize
that the finding no differences in malignancies was due to
the rarity of events. Most studies have not focused on
malignancy because it is not the main cause of morbidity
and mortality in patients with SLE and ESRD. Similar to
cardiovascular diseases, as survival improves, malignancy
will become an important issue in these patients and
longer-term follow-up will be required.
Differences between treatment modalities were
observed among orthopedic complications and bleeding
risk. AVN was the main orthopedic complication in
patients with SLE and ESRD and AVN was more common
in the PD group than in the others. When previous studies
involving patients with SLE and ESRD were reviewed,
uremia, rejection, and steroid dosage were related to AVN
[16-18]. However, controversies exist regarding the dosage
of steroids used. With the exception of a few studies that
focused on KT, few data exist on the orthopedic complica-
tions in patients with SLE and ESRD. Thus, further inves-
tigations are needed to establish AVN incidence and risk
factors. Bleeding was more common in the HD group.
Previous studies have investigated thrombotic complica-
tions related to the presence of antiphospholipid antibod-
ies [3,19] because renal allograft thrombosis and vascular
access were the main causes of morbidity in patients hav-
ing SLE with antiphospholipid antibodies. In this study,
none of the patients had antiphospholipid antibodies, but
bleeding risks in the HD group were higher, which may
have been related to anticoagulation factors such as
heparin for HD.
SLE with renal involvement is a known risk factor of
DM and HTN [20,21]. However, only small amounts of
data are available on the differences among the three
treatment modalities and the incidence of DM and HTN.
Comparisons using simple changes in numbers or doses
of medication are not the best way to make an objective
determination and the current study was influenced by
differences in the time of follow-up. Aggravated DM or
HTN was not significantly different between groups when
adjusted for follow-up period. However, more meaningful
data will be obtained with a longer follow-up of the HD or
PD group.
When previous studies on survival were reviewed, the
cumulative survival rates following development of ESRD
were 83-92% at 5 years in patients receiving HD, 53-80%
in patients treated with PD, and 85-97% in patients
receiving KT [3,4,19,22]. Compared to other studies, sur-
vival in the HD group in this study was poorer, whereas
survival of patients in the PD group was better, while sur-
vival of patients in the KT group was similar to that of the
PD group. We hypothesize that differences in patient sur-
vival between the HD and PD groups were due to two fac-
tors. First, HD is the preferred treatment for patients in
poor general condition, which is related to poor survival
rates. Second, long-term follow up of patients in the PD
group in this study indicate good disease control and thus
better survival rates. This is in contrast to reports that in
the short term, disease control in patients receiving PD is
poor but not significantly different from that in patients
undergoing HD when compared over longer periods of
time [3]. When compared to other studies, the present
study showed longer time on dialysis prior to KT (HD,
30.3 ± 32.3 months; PD, 36.6 ± 39.6 months). All trans-
planted kidneys came from living donors and advanced
immunosuppressants such as tacrolimus were used
[4,6,22,23]. Note that controversies regarding the rela-
tionship between dialysis time and KT prognosis exist and
since disease control prior to KT is critical to survival, we
hypothesized that long dialysis time pre-KT implied good
disease control. Comparing the study conducted by Ward
[4] with that of Moroni et al. [22], longer dialysis time was
associated with better survival (dialysis time, 21 months
vs. 42 months; 5 year survival, 83% vs. 97%, respectively).
However, further investigations are needed to substanti-66 The Korean Journal of Internal Medicine Vol. 26, No. 1, March 2011
ate this association. Considering good patient survival
rates and a low rate of perioperative and postoperative
risks associated with KT (except for one perinephric
hematoma recovered by conservative care), we recom-
mend that KT should not be delayed.
In conclusion, the present study was aimed at assessing
the long-term clinical outcomes of patients with ESRD
secondary to SLE using adequate numbers of patients.
This study focused on subjective or objective clinical out-
comes in a multicenter retrospective design and did not
rely simply on disease activity. Our results demonstrate
that KT has better survival and lower complication rates
than HD and lower complication rates than PD. The prog-
nosis was similar when comparing HD with PD since PD
was better than HD across most study outcomes, although
the technique survival rate of PD was lower than HD.
Thus, if KT is not a viable option, we believe that an alter-
native treatment option should take into consideration the
patient’s general condition and preference. Limitations,
however, exist to interpreting the data. The first was our
inability to control variables such as age, immunosuppres-
sant use, and disease duration in a retrospective format.
The second was that when comparing survival rates, we
disregarded the duration of RRT prior to KT. Finally, due
to the rarity of ESRD secondary to lupus nephritis, we
could not recruit a sufficient number of patients to give
the study adequate statistical power. These limitations can
be overcome with additional prospective studies that take
into account these variables and recruit sufficient num-
bers of patients.
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